US 12,419,971 B2
Diet controlled expression of a nucleic acid encoding a pro-apoptotic protein
Pierre Fafournoux, Auriers (FR); and Jacques Mallet, Paris (FR)
Assigned to INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION L'ENVIRONNEMENT, Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); SORBONNE UNIVERSITE, Paris (FR); ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS, Paris (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); and INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE, Paris (FR)
Filed by INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); SORBONNE UNIVERSITE, Paris (FR); ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS, Paris (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); and INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE, Paris (FR)
Filed on Dec. 26, 2019, as Appl. No. 16/727,647.
Application 16/727,647 is a division of application No. 16/306,832, abandoned, previously published as PCT/EP2017/063422, filed on Jun. 2, 2017.
Claims priority of provisional application 62/345,162, filed on Jun. 3, 2016.
Prior Publication US 2020/0188533 A1, Jun. 18, 2020
Int. Cl. A61K 48/00 (2006.01); A01K 67/0275 (2024.01); A61K 35/00 (2006.01); A61K 45/06 (2006.01); C07K 14/705 (2006.01); C12Q 1/6897 (2018.01)
CPC A61K 48/0058 (2013.01) [A01K 67/0275 (2013.01); A61K 35/00 (2013.01); A61K 45/06 (2013.01); C07K 14/70575 (2013.01); C12Q 1/6897 (2013.01); A01K 2207/25 (2013.01); A01K 2217/30 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); A01K 2267/0393 (2013.01); C12N 2740/16043 (2013.01); C12N 2830/30 (2013.01)] 10 Claims
 
1. A method for eliminating infused cells which contain a nucleic acid comprising:
a regulatory polynucleotide comprising a minimal promoter and at least one AARE (amino acid response element) nucleic acid, the regulatory polynucleotide being activated in a human individual upon consumption of a diet deficient in at least one essential amino acid; and
a suicide safety gene selected from the group consisting of: BCL2 modifying factor, Apoptosis inducer NBK, Apoptotic protease-activating factor 1 (APAF1, CED4), BAX, Endophilin B1, FADD, CRADD, FAS, Modulator of apoptosis 1, SMAC, Endonuclease G, HRK, Serine protease HTRA2, p53, NOXA, RIPK1, Bcl2 binding component 3, PMAIP1, Tumor necrosis factor receptor superfamily member 10A Precursor (Death receptor 4), caspase 1, caspase 3, caspase 7, caspase 8, and caspase 9, the product of which is associated with the killing of cells, said suicide safety gene being placed under the control of the regulatory polynucleotide, the method comprising:
a) administering the infused cells to a human individual in need of cancer treatment or regenerative medicine, and then
b) eliminating the infused cells by inducing programmed cellular death into at least one of the infused cells by submitting the human individual to a diet deficient in at least one essential amino acid.